Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK.

The opening ceremony was attended by Hyoung-Ki Kim, CEO and Vice Chairman at Celltrion, Rosalind Campion, Director of the Office for Life Sciences and Mark Samuels, Chief Executive of Medicines UK, and the British Biosimilars Association.

Strategically located in the heart of Uxbridge, the new office will serve as Celltrion UK’s central hub for UK operations. This move places Celltrion among a growing list of life sciences companies, including Regeneron, Amgen, Gilead Sciences, Daiichi Sankyo, that have established a presence in Uxbridge, a hub for biotechnology and pharmaceutical innovation.

Speaking at the opening ceremony, Hyoung-Ki Kim, CEO and Vice Chairman of Celltrion, said, “The opening of our new UK office marks a pivotal milestone in Celltrion UK history. This demonstrates our strong commitment to the UK, a strategic market for our growth. We are here for the long term and are invested in the future of biosimilars in the UK. We look forward to continued collaboration with local institutions and regulatory bodies to ensure sustainable access to high-quality biologic treatments.”

This move is the latest chapter in Celltrion’s long-term vision for the UK, demonstrating its dedication to being a trusted healthcare partner, a contributor to the UK economy, and a key player in the global biosimilars market.